Integra LifeSciences Holdings Corporation (IART)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,372 | 1,542 | 1,558 | 1,542 | 1,611 | 1,635 | 1,648 | 1,674 |
| Operating profit | $m | 68 | 656 | ||||||
| Net profit | $m | 134 | 169 | 181 | 68 | -7 | -516 | - | 189 |
| EPS reported | $ | -6.73 | -0.09 | ||||||
| Operating cashflow per share | $ | 0.66 | 1.09 | ||||||
| Capex per share | $ | 1.25 | 0.60 | ||||||
| FCF per share | $ | -0.59 | 0.50 | ||||||
| Free cash flow | $m | -45 | 39 | ||||||
| Net debt | $m | 1,592 | 1,765 | ||||||
| Book value equity | $m | 1,043 | 1,051 | ||||||
| Book value per share | $ | 13.60 | 13.44 | ||||||
| Number of shares | m | 76.75 | 78.17 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.91 | 0.91 | ||||||
| P/S LTM | x | 0.58 | 0.58 | ||||||
| P/FCF LTM | x | -21.06 | 24.60 | ||||||
| EV/EBITDA LTM | x | -8.43 | 11.06 | ||||||
| EV/Sales LTM | x | 1.68 | 1.97 | ||||||
| Earnings Yield LTM | % | -54.18% | -0.51% | ||||||
| FCF Yield | % | -4.75% | +4.07% | ||||||
| Quality | |||||||||
| ROE | % | -49.50% | -0.69% | ||||||
| ROIC | % | +1.91% | +19.92% | ||||||
| Operating margin | % | +4.18% | +39.81% | ||||||
| Gross margin | % | +51.69% | +53.74% | ||||||
| FCF/Sales | % | -2.77% | +2.35% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1.53% | +2.31% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | +55.24% | ||||||
| Operating Profit Growth | % | +140.46% | +2208.5% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.02 | 0.02 | ||||||
| Net Debt/EBITDA | x | -5.51 | 7.34 | ||||||
| EBIT/Net interest | x | 0.79 | 6.82 | ||||||
| Net debt/market cap | % | +1.95% | +1.31% | ||||||
| Net debt/Equity | x | 1.53 | 1.68 | ||||||
| Gross debt/equity | x | 1.95 | 1.94 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Integra LifeSciences Holdings Corporation (IART)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free